The Reality of Puerto Rico after Maria
Big Pharma Provides Resilience and Hope
Genomics Gets Personal
Despite Data and Privacy Challenges, Decreasing Cost Ushers in the Age of Personalized Whole-Genome Sequencing
Top 10 Under 40
Biopharma Research and Businesses Benefit from Contributions of Emerging Leaders
Mass Spec Is Being Souped Up to Help It Keep Up
A Few Modifications Might Enhance Performance
For full access to this article login to GEN Select now.
Injecting New Life into Cell-Based Assays
Late-Stage Drug Failures Prompt Push for More Effective Approaches to Designing Therapies
- Cell-based assays continue to provide powerful tools to fuel drug discovery. However, costly late-stage failures are driving the industry’s search for improved approaches and novel tools for interrogating cells. Throughput, reliability, cost, and physiologic relevance of cellular models for predictive toxicology remain central issues in the field. Visiongain’s ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.